Matches in SemOpenAlex for { <https://semopenalex.org/work/W179620888> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W179620888 endingPage "6" @default.
- W179620888 startingPage "23" @default.
- W179620888 abstract "Chemotherapy has had limited success in biliary tract cancer. Of the newer agents, gemcitabine (Gemzar) and irinotecan (CPT-11, Camptosar) both have single-agent activity in patients with advanced disease. We conducted a phase II trial to study the efficacy and toxicity of the combination of gemcitabine plus irinotecan in patients with locally advanced or metastatic biliary tract cancer. The study has enrolled 14 patients with histologically or cytologically documented cancer of the biliary tract or gallbladder with bidimensionally measurable disease, Eastern Cooperative Oncology Group performance status 0 or 1, decompressed biliary tree, and no prior exposure to chemotherapy. Gemcitabine at 1,000 mg/m2 and irinotecan at 100 mg/m2 were both administered on days 1 and 8, every 21 days. In patients who had less than grade 3 hematologic and less than grade 2 nonhematologic toxicity following cycle 1, the dose of irinotecan was increased to 115 mg/m2 for subsequent cycles. A total of 65 cycles of chemotherapy have been administered, with an average of 4.5 cycles per patient (range: 1 to 11 cycles). The median treatment duration was 3 months (range: 0.75 to 8 months). An objective partial response was determined radiographically in two patients (14%) while stable disease for periods ranging from 4 to 11.5 months was noted in six patients (43%). Toxicity consisted of grade 3/4 neutropenia in seven patients (50%) with no episodes of febrile neutropenia, grade 3/4 thrombocytopenia in four (28%), grade 3 diarrhea in two (14%), and grade 3 nausea in one patient. The combination of gemcitabine plus irinotecan appears to possess modest clinical activity, and it is well tolerated in patients with advanced biliary cancer. Patient accrual is ongoing to this study." @default.
- W179620888 created "2016-06-24" @default.
- W179620888 creator A5003322868 @default.
- W179620888 creator A5029567437 @default.
- W179620888 creator A5042529049 @default.
- W179620888 creator A5061691527 @default.
- W179620888 creator A5080279648 @default.
- W179620888 creator A5080913413 @default.
- W179620888 date "2003-09-01" @default.
- W179620888 modified "2023-10-16" @default.
- W179620888 title "Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report." @default.
- W179620888 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14569844" @default.
- W179620888 hasPublicationYear "2003" @default.
- W179620888 type Work @default.
- W179620888 sameAs 179620888 @default.
- W179620888 citedByCount "15" @default.
- W179620888 countsByYear W1796208882012 @default.
- W179620888 countsByYear W1796208882014 @default.
- W179620888 countsByYear W1796208882017 @default.
- W179620888 countsByYear W1796208882020 @default.
- W179620888 countsByYear W1796208882022 @default.
- W179620888 crossrefType "journal-article" @default.
- W179620888 hasAuthorship W179620888A5003322868 @default.
- W179620888 hasAuthorship W179620888A5029567437 @default.
- W179620888 hasAuthorship W179620888A5042529049 @default.
- W179620888 hasAuthorship W179620888A5061691527 @default.
- W179620888 hasAuthorship W179620888A5080279648 @default.
- W179620888 hasAuthorship W179620888A5080913413 @default.
- W179620888 hasConcept C121608353 @default.
- W179620888 hasConcept C126322002 @default.
- W179620888 hasConcept C141071460 @default.
- W179620888 hasConcept C2776694085 @default.
- W179620888 hasConcept C2776907518 @default.
- W179620888 hasConcept C2777063308 @default.
- W179620888 hasConcept C2778822529 @default.
- W179620888 hasConcept C2778850193 @default.
- W179620888 hasConcept C2780258809 @default.
- W179620888 hasConcept C2780259306 @default.
- W179620888 hasConcept C526805850 @default.
- W179620888 hasConcept C71924100 @default.
- W179620888 hasConcept C90924648 @default.
- W179620888 hasConceptScore W179620888C121608353 @default.
- W179620888 hasConceptScore W179620888C126322002 @default.
- W179620888 hasConceptScore W179620888C141071460 @default.
- W179620888 hasConceptScore W179620888C2776694085 @default.
- W179620888 hasConceptScore W179620888C2776907518 @default.
- W179620888 hasConceptScore W179620888C2777063308 @default.
- W179620888 hasConceptScore W179620888C2778822529 @default.
- W179620888 hasConceptScore W179620888C2778850193 @default.
- W179620888 hasConceptScore W179620888C2780258809 @default.
- W179620888 hasConceptScore W179620888C2780259306 @default.
- W179620888 hasConceptScore W179620888C526805850 @default.
- W179620888 hasConceptScore W179620888C71924100 @default.
- W179620888 hasConceptScore W179620888C90924648 @default.
- W179620888 hasIssue "9 Suppl 8" @default.
- W179620888 hasLocation W1796208881 @default.
- W179620888 hasOpenAccess W179620888 @default.
- W179620888 hasPrimaryLocation W1796208881 @default.
- W179620888 hasRelatedWork W179620888 @default.
- W179620888 hasRelatedWork W1987606751 @default.
- W179620888 hasRelatedWork W1990777236 @default.
- W179620888 hasRelatedWork W2003291927 @default.
- W179620888 hasRelatedWork W2075985874 @default.
- W179620888 hasRelatedWork W2098455424 @default.
- W179620888 hasRelatedWork W2124597836 @default.
- W179620888 hasRelatedWork W2162728253 @default.
- W179620888 hasRelatedWork W2314946743 @default.
- W179620888 hasRelatedWork W2416780622 @default.
- W179620888 hasVolume "17" @default.
- W179620888 isParatext "false" @default.
- W179620888 isRetracted "false" @default.
- W179620888 magId "179620888" @default.
- W179620888 workType "article" @default.